GSK malaria vaccine could save millions of lives

The following report published in The Guardian today provides encouraging global health news — GSK’s new vaccine against malaria has been shown to halve the risk of malaria.

Malaria vaccine could save millions of children’s lives

Millions of small children’s lives could be saved by a new vaccine that has been shown to halve the risk of malaria in the first large-scale trials across seven African countries.

The long-awaited results of the largest-ever malaria vaccine study, involving 15,460 babies and small children, show that it could massively reduce the impact of the much-feared killer disease. Malaria takes nearly 800,000 lives every year – most of them children under five. It damages many more.

The vaccine has been in development for two decades – the brainchild of scientists at the UK drug company GlaxoSmithKline, which has promised to sell it at no more than a fraction over cost-price, with the excess being ploughed back into further tropical disease research.

Milestone reached in Measles vaccination

The United Nations Foundation reported today that one billion children in more than 60 developing countries have been immunized against measles since 2001 — the start of the Measles Initiative.

In 1980, before widespread vaccination, measles caused an estimated 2.6 million deaths each year. With accelerated immunization activities spearheaded by governments and the Measles Initiative, global measles mortality has decreased by an impressive 78 percent worldwide from 733,000 deaths in 2000 to 164,000 in 2008. Reductions in measles-related deaths during that same time period accounts for nearly a quarter (24 percent) of the overall decrease in childhood mortality, representing significant progress toward Millennium Development Goal 4 (MDG4).

 

UN protects millions of children in DR Congo with anti-measles vaccination

Some 3.1 million children in the Democratic Republic of the Congo (DRC) have been vaccinated against measles in a United Nations-coordinated campaign to combat the disease outbreak which has claimed the lives of 1,145 children since the start of this year.

The measles epidemic affected a total of 115,600 children between January and June, the UN Office for the Coordination of Humanitarian Affairs (OCHA) said in a press release issued yesterday, adding that the vaccination campaign was funded with $1.9 million.

The campaign, which kicked off on 10 May, was coordinated by the UN World Health Organization (WHO) in the provinces of Katanga, Kasai Occidental, Bas-Congo, Equateur and Orientale.  “The funding – equivalent to 61 cents per child – helped protect the health of millions of children,” said Fidèle Sarassoro, the UN Humanitarian Coordinator for DRC.

Measles is a highly contagious viral disease, which mostly affects children. It is transmitted through droplets from the nose, mouth or throat of infected persons. Initial symptoms, which usually appear between eight to 12 days after infection, include high fever, a running nose, bloodshot eyes, and tiny white spots on the inside of the mouth. A rash then develops, starting on the face and upper neck and gradually spreading to the rest of the body.

In malnourished children and people with reduced immunity, the disease can cause serious complications, including blindness, encephalitis, severe diarrhoea, ear infection, pneumonia and even death.

Source – UN Daily News

Dengue – new site highlights disease information and research

Population growth, urbanization and rapid mass transportation have resulted in an explosive increase in dengue cases – from 1.2 million in 1998 to as many as 500 million annual cases today – and contributed to an ever growing number of countries and people at risk of infection. Dengue is now endemic in over 100 countries across the globe, and is the most prevalent mosquito-borne viral disease.

The Dengue Vaccine Initiative just launched a new site to provide a central resource for information about the disease, vaccines and other efforts.

Substantial progress towards finding a vaccine has been made in the last decade. Several vaccines are in various stages of advanced development, with clinical trials currently underway on five candidate vaccines. Trials in the most advanced stages are showing encouraging preliminary data.

Dengue is a major cause of morbidity and mortality and a leading cause of hospitalization of children in many countries in tropical and subtropical areas of the world. The greatest documented burden of dengue occurs in Asia and Latin America, but the disease is now appearing in previously unaffected areas. The cost of illness to society is considerable, from lost wages and decreased productivity to costs associated with seeking care and direct medical expenses. An estimated 60% of the economic strain caused by dengue is a result of indirect costs. The cost of dengue in the Western Hemisphere alone is estimated at $2.1 billion per year.

 

Resolutions and highlights from the 2011 World Health Assembly

An interesting synopsis of key resolutions, decisions and highlights from the 2011 World Health Assembly, courtesy of World Health Advocacy.  The World Health Assembly, held in Geneva Switzerland, started May 16th and closed today.

This year’s World Health Assembly saw an unprecedented social engagement, with updates and discussions being shared via twitter, facebook and other media. The global discussion was significant enough to cause Dr. Chan to comment on it in her closing speech – “tweets about events over the past several days, on topics ranging from the reform agenda for WHO to pandemic influenza preparedness, reached more than three million people.”

More than 2700 delegates, including Health Ministers and senior health officials from 192 WHO Member States, NGOs and civil society groups attended the World Health Assembly in person. Following a week’s worth of discussions, the following are some of the key resolutions and highlights:

Non-communicable diseases

Countries unanimously approved a resolution on the preparations for the United Nations General Assembly high-level meeting on the prevention and control of non-communicable diseases being held this September. Some 47 countries and 16 observers, including civil society, commented on the resolution, which urges heads of state and governments to attend the UN meeting in New York and calls for steps against the NCD challenge through an action-oriented outcome document.

Read the WHO report.

Working together to stop HIV/AIDS

The Global Health Sector Strategy on HIV/AIDS, 2011-2015 was approved, and will guide actions by WHO and governments around the world to dramatically increase innovation, integration and efficiencies of HIV programmes. If all countries implement these guidelines, at least 4.2 million new HIV infections could be prevented and 2 million lives saved between 2011-2015.

Global immunization vision and strategy

In a great show of support, many delegates and global health partners in Committee A spoke in favour of the Global Immunization Vision and Strategy. Delegates applauded strides in saving lives around the world through vaccines, noting key challenges such as eradicating polio and increasing measles vaccination coverage to prevent dangerous outbreaks.

Read the report and strategic direction for the Decade of Vaccines.

The final mile in polio

Delegates described significant advances in polio eradication over the past year. In India and Nigeria, polio cases plummeted by 95% between 2009 and 2010. Highlighting the necessity of routine immunization, delegates pointed to the funding gap of US$ 665 million, and warned that a lack of resources could lead to dangerous backslide. Several delegates called for political and financial commitments, noting that low-income countries could save US$ 40-50 billion over the next 25 years.

Maternal, infant and young child nutrition

More than 100 million children under five were underweight in 2010. Additionally, more women are becoming overweight, increasing the risk of birth complications. Delegates in Committee B discussed a progress report on a plan to tackle problems of poor nutrition through awareness campaigns, and policies involving health, education and agriculture.

Resolutions and reports support health-related MDGs

Health-related MDGs received support with resolutions and reports on immunization strategy, infant and young child nutrition, child injury prevention, safe management of drinking water, malaria, and the presentation of the final report of the Commission on Information and Accountability for Women’s and Children’s Health.

Cholera: mechanism for control and prevention

Delegates agreed that cholera is a public health threat for many countries and the incidence is on the rise. They expressed the urgent need for effective public health interventions, such as solid surveillance systems, improved environmental management, access to clean water and proper sanitation, and the adequate use of cholera vaccines as a complementary measure. Cholera was recognized as a clear marker of environmental management. Member States underscored the need to revitalize the Global Task Force on Cholera Control and emphasized the need to scale up advocacy measures.

Annual report on the eradication guinea-worm disease

The delegates adopted a resolution paving the way for an annual report on the eradication of dracunculiasis (more commonly known as guinea-worm disease) to be presented every year beginning with the next Health Assembly. Dracunculiasis is the second disease which is approaching eradication (the first being smallpox) and it occurs only after people drink contaminated water. Previously it was responsible for millions of infections across Africa and Asia. The disease mainly occurs in remote poverty-stricken areas, with limited or no access to safe drinking water.

Sources:

• Sixty-fourth World Health Assembly: daily notes on proceedings
• Historical agreements at the Sixty-fourth World Health Assembly

Polio vaccination campaign aims to reach 14m children

With a polio outbreak spreading rapidly in the Democratic Republic of the Congo (DRC), UN Daily News reports that the Executive Director of UNICEF will visit the country to help support a mass campaign to vaccinate over 14 million children.

The DRC has witnessed a sharp resurgence of polio as conditions in the country continue to complicate vaccination efforts, potentially undermining global eradication of the crippling disease. From January 2010 to February 2011, there were 112 new cases. In 2009, only three cases were detected.

“UNICEF will do everything we can to support the DRC’s collective effort to defeat this evil virus once and for all,” said UNICEF’s Executive Director, Anthony Lake. “Eradicating polio in DRC and everywhere requires an absolute commitment by government and its partners to vaccinate every child.”

In response to the outbreak, preparations are underway to go door to door to vaccinate more than 14 million children by the end of May. The aim is to make sure that no child is left unprotected.

 

GAVI welcomes a new global commitment to vaccines

A new partnership was announced today, injecting additional funding into the Global Alliance for Vaccines and Immunisation’s (GAVI) efforts to help save millions of children.  His Highness Sheikh Mohamed bin Zayed Al Nahyan, the Crown Prince of Abu Dhabi and Deputy Supreme Commander of the UAE Armed Forces, and the Bill & Melinda Gates Foundation entered into a partnership in which each committed US$ 50 million for immunisation programmes in Afghanistan and Pakistan.

GAVI will receive US$ 66 million to buy and deliver additional supplies of the five-in-one pentavalent vaccine and to support the introduction of new pneumococcal vaccines in Afghanistan. These vaccines help protect children from the main killers of children under five, including pneumonia, diphtheria, pertussis (whooping cough), tetanus, hepatitis B, Haemophilus influenzae type B (HiB), which causes meningitis.

“Private donations like this send a clear signal to our government donors that they are not alone in seeing the value of immunisation,” said Dagfinn Høybråten, Chair of the GAVI Alliance board.

Backed by the Bill & Melinda Gates Foundation and an increasing number of sovereign governments since its launch in 2000, the GAVI Alliance has succeeded in immunising more than 288 million children, preventing more than five million premature deaths, according to WHO figures.

If fully funded, the GAVI Alliance will be able to immunise an additional 230 million children with pentavalent vaccine by 2015, and protect 90 million children with new pneumococcal vaccines which are already being introduced in the first of more than 40 developing countries. GAVI also plans to introduce vaccines against rotavirus in 33 countries.

Joint venture aims to develop new rotavirus vaccine for poor

A joint venture between U.S. drugmaker Merck and Britain’s Wellcome Trust charity is working on an oral rotavirus vaccine designed to be cheaper and easier to use than current shots, as reported by Reuters.

The vaccine will aim to protect against diarrhoea-causing rotavirus infections and will be based on thin strips or granules that dissolve in the mouth and can be easily transported, stored and administered.  Currently available rotavirus shots, made by Merck & Co. and GlaxoSmithKline, need to be kept in cold storage — making their transportation and delivery complex and costly.

Diarrhoea is one of the top two killers of children under five worldwide, and rotavirus is the leading cause of severe diarrhoeal disease in children. Each year, rotavirus-related diarrhoea kills more than 500,000 children and is the cause of many millions more needing hospital treatment.

Vaccines are often the best hope for tackling many diseases in poor countries.

Progress in global public health threatened by funding shortfalls

Last year was full of “big events” for public health, including the launch of a new meningitis vaccine and an aggressive new strategy for polio eradication, the head of the United Nations health agency said today, while stressing the need to ensure that progress is maintained in the year ahead.  (UN Daily News)

Margaret Chan, Director-General of the World Health Organization (WHO), noted in her address to the agency’s Executive Board in Geneva that a major issue is how much the financial crisis and economic downturn will affect public health, both internationally and within individual countries.

“Will progress stall? Will powerful innovations, like the meningitis vaccine, like the vaccines for preventing diarrhoeal disease and pneumonia, like the new diagnostic test for tuberculosis, fall short of reaching their potential?”

The Director-General noted that many organizations in global health, like the Global Fund to Fight AIDS, Tuberculosis and Malaria, the Global Alliance for Vaccines and Immunization (GAVI Alliance), and WHO itself, now face serious funding shortfalls.

In her wide-ranging speech, Ms. Chan also noted that experience showed that health initiatives survive long enough to deliver sustainable results only when they are nationally owned and aligned with national priorities and capacities.

“Self-reliance is realized only when programmes are delivered in ways that strengthen existing systems, infrastructures and capacities. Doing so helps countries reduce their dependence on aid and gives donors an exit strategy.”

 

New malaria vaccine shows long-lasting protection

(From Reuters) An experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection, though its effectiveness declines slightly over time, according to recently published trial data.  Scientists conducting the mid-stage trial at the Kenya Medical Research Institute said results showing the shot offered 46 percent protection for 15 months meant it had “promise as a potential public health intervention against childhood malaria in malaria endemic countries.”

Malaria is an infectious disease spread by mosquitoes that threatens up to half the world’s population. Most of its victims are children under five in poor countries in sub-Saharan Africa.

Late-stage trials of the GSK vaccine, known as RTS,S or Mosquirix, in 16,000 children in seven countries across Africa are ongoing, with immunizations due to end next month.  If data show the vaccine was effective, it could be licensed and rolled out as soon as 2015.

GSK chief executive Andrew Witty has said that if RTS,S proved effective in final-stage trials it would be sold at a price that those who need it most can afford. The company has said it was planning for a profit margin of 5 percent over the cost of making the vaccine, and that would be reinvested in new vaccines for malaria and other neglected diseases.